OMERS ADMINISTRATION Corp Acquires 114,500 Shares of Emergent Biosolutions Inc. $EBS

Key Points

• OMERS ADMINISTRATION Corp significantly increased its stake in Emergent Biosolutions, acquiring 114,500 shares and raising its total ownership to approximately 146,700 shares.
• Analyst ratings for Emergent Biosolutions have varied, with the stock receiving a downgrade from a "buy" to a "hold" rating, despite three analysts still maintaining a "buy" consensus.
• The company reported better than expected earnings per share (EPS) of $0.16, surpassing analysts' estimates of -$0.26, indicating a positive performance amidst mixed revenue results.

OMERS ADMINISTRATION Corp raised its stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 355.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 146,700 shares of the biopharmaceutical company's stock after purchasing an additional 114,500 shares during the period. OMERS ADMINISTRATION Corp owned approximately 0.27% of Emergent Biosolutions worth $713,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of EBS. SBI Securities Co. Ltd. lifted its holdings in shares of Emergent Biosolutions by 95.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 6,313 shares during the period. Corton Capital Inc. bought a new position in shares of Emergent Biosolutions during the 1st quarter worth about $70,000. Bank of New York Mellon Corp lifted its holdings in shares of Emergent Biosolutions by 40.4% during the 1st quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 4,894 shares during the period. EP Wealth Advisors LLC bought a new position in shares of Emergent Biosolutions during the 4th quarter worth about $110,000. Finally, Alpine Global Management LLC bought a new position in shares of Emergent Biosolutions during the 4th quarter worth about $112,000. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Trading Down 0.9%

NYSE EBS traded down $0.07 during trading on Friday, reaching $7.57. 830,234 shares of the stock traded hands, compared to its average volume of 1,146,840. The firm has a market cap of $403.59 million, a price-to-earnings ratio of 3.09 and a beta of 2.04. The stock's 50-day moving average price is $7.58 and its 200 day moving average price is $6.42. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $12.73.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.42. The firm had revenue of $140.90 million during the quarter, compared to analysts' expectations of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. Analysts predict that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 7,086 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $8.87, for a total value of $62,852.82. Following the transaction, the director owned 71,799 shares of the company's stock, valued at approximately $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the transaction, the director directly owned 137,659 shares in the company, valued at approximately $1,190,750.35. The trade was a 5.39% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

EBS has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Emergent Biosolutions in a report on Wednesday. Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Emergent Biosolutions presently has a consensus rating of "Buy" and an average price target of $14.33.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.